論文

査読有り 国際誌
2020年

Pilot study of a basic individualized cognitive behavioral therapy program for chronic pain in Japan.

BioPsychoSocial medicine
  • Hiroki Hosogoshi
  • Kazunori Iwasa
  • Takaki Fukumori
  • Yuriko Takagishi
  • Yoshitake Takebayashi
  • Tomonori Adachi
  • Yuki Oe
  • Yukino Tairako
  • Yumiko Takao
  • Hiroyuki Nishie
  • Ayako Kanie
  • Masaki Kitahara
  • Kiyoka Enomoto
  • Hirono Ishii
  • Issei Shinmei
  • Masaru Horikoshi
  • Masahiko Shibata
  • 全て表示

14
6
開始ページ
6
終了ページ
6
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1186/s13030-020-00176-w

Background: Chronic pain is a major health problem, and cognitive behavioral therapy (CBT) is its recommended treatment; however, efforts to develop CBT programs for chronic pain and assess their feasibility are remarkably delayed in Asia. Therefore, we conducted this pilot study to develop a basic individualized CBT for chronic pain (CBT-CP) and assessed its feasibility for use in Japan. Methods: Our study was an open-labeled before-after trial without a control group conducted cooperatively in five Japanese tertiary care hospitals. Of 24 outpatients, 15, age 20-80, who experienced chronic pain for at least three months were eligible. They underwent an eight-session CBT-CP consisting of relaxation via a breathing method and progressive muscle relaxation, behavioral modification via activity pacing, and cognitive modification via cognitive reconstruction. The EuroQol five-dimensional questionnaire five level (EQ5D-5 L) assessment as the primary outcome and quality of life (QOL), pain severity, disability, catastrophizing, self-efficacy, and depressive symptoms as secondary outcomes were measured using self-administered questionnaires at baseline, post-treatment, and 3-month follow-up. Intention-to-treat analyses were conducted. Results: Effect size for EQ5D-5 L score was medium from baseline to post-treatment (Hedge's g = - 0.72, 90% confidence interval = - 1.38 to - 0.05) and up to the 3-month follow-up (g = - 0.60, CI = - 1.22 to 0.02). Effect sizes for mental and role/social QOL, disability, catastrophizing, self-efficacy, and depressive symptoms were medium to large, although those for pain severity and physical QOL were small. The dropout rate was acceptably low at 14%. No severe adverse events occurred. Conclusion: The findings suggest that CBT-CP warrants a randomized controlled trial in Japan. Trial registration: University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), UMIN000020880. Registered on 04 February 2016.

リンク情報
DOI
https://doi.org/10.1186/s13030-020-00176-w
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32175003
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063808
ID情報
  • DOI : 10.1186/s13030-020-00176-w
  • PubMed ID : 32175003
  • PubMed Central 記事ID : PMC7063808

エクスポート
BibTeX RIS